iSTAR Medical’s glaucoma device MINIject shows positive one-year results in European trial

16 November 2020

Growing body of evidence confirms MINIject is safe and effective with results sustained over time.

Wavre, Belgium: 16 November 2020 – iSTAR Medical, a medtech company developing minimally invasive ophthalmic implants for treatment of patients with glaucoma, today announced positive one-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIjectTM. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held 13-15 November 2020.

  • Positive one-year results from the STAR-II European trial sustain the remarkable six-month outcomes and are consistent with the STAR-I trial results at one year

  • Promising MINIject data at two years from the STAR-I trial were recently published in the British Journal of Ophthalmology

  • Pre-clinical studies of MINIject highlighting the anti-fibrotic properties of its STAR® material were recently published in BMC Biomedical Engineering

STAR-II results at one year

At one-year follow-up, mean intraocular pressure (IOP) was 15.1mm Hg, corresponding to a 38 percent reduction from medicated baseline IOP. Moreover, 45 percent of patients did not require any IOP-lowering medication one year after intervention (from a mean of 2.9 medications at baseline). In a post-hoc analysis in medication-free patients, IOP was reduced further by 46 percent to 13.1mm Hg at one year. There were no significant overall safety issues, nor concerns with corneal health.

More info on iSTAR Medical‘s website.